The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines
Open accessAbstract
Paclitaxel (PTX) is one of the most potent cancer drugs; however, its low solubility and strong systemic side effects limit its clinical applications. To overcome these issues, new drug formulations and chemical modifications have been proposed. In this study, we present conjugation of PTX to hybrid collagen-cell penetrating peptide (COL-CPP) carriers. The peptide carrier is highly soluble and utilizes a unique stabilization strategy: folding into a triple helix. Here, we report the formation of PTX-COL-CPP prodrug that has similar drug potency as free PTX when tested in Jurkat (human T lymphocyte of acute T cell leukemia) cells but not in A549 (human epithelial of lung carcinoma) cells. Confocal images and flow cytometry show that this behavior originates from lower cellular uptake of COL-CPP and endosomal entrapment of the prodrug in A549, but not in Jurkat cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conjugation or recombinant fusion of therapeutic agents such as cetuximab or lumican to a collagen‐binding domain peptide can increase efficacy and safety [79, 80].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How Taxol/paclitaxel kills cancer cells
Weaver, B. A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0916 · Cited by 1,547
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Polymer conjugates: nanosized medicines for treating cancer
Vicent, M. J., & Duncan, R. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2005.11.006 · Cited by 443
Taxol (paclitaxel): mechanisms of action.
Horwitz, S. B. (1994) · PubMed · Cited by 434
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Discovering and improving novel peptide therapeutics
MCGREGOR, D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.002 · Cited by 331
Bhattacharyya, J., Bellucci, J. J., Weitzhandler, I., McDaniel, J. R., Spasojevic, I., Li, X., Lin, C.-C., Chi, J.-T. A., & Chilkoti, A. (2015) · Nature Communications · doi:10.1038/ncomms8939 · Cited by 227
Deutsch, H. M., Glinski, J. A., Hernandez, M., Haugwitz, R. D., Narayanan, V. L., Suffness, M., & Zalkow, L. H. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00124a011 · Cited by 221
Duncan, R., Gac-Breton, S., Keane, R., Musila, R., Sat, Y. N., Satchi, R., & Searle, F. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00328-5 · Cited by 195
Research works printed but not linked: 1
- Horowitz S. B., 1994, Ann. Oncol., 5, S3
Cited by
The role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Is prodrug design an approach to increase water solubility?
Sanches, B. M. A., & Ferreira, E. I. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118498 · Cited by 116
Extracellular matrix functions in lung cancer
Götte, M., & Kovalszky, I. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.02.018 · Cited by 78
Anuradha, A., Patel, S., Patle, R., Parameswaran, P., Jain, A. K., & Shard, A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.005 · Cited by 72
Metadata
- Authors
- Ayalew, L., Acuna, J., Urfano, S. F., Morfin, C., Sablan, A., Oh, M., Gamboa, A., & Slowinska, K.
- Affiliations
- California State University, Long Beach (US)
- Corresponding author
- Slowinska, Katarzyna
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-08-01
- Volume
- 8
- Issue
- 8
- Pages
- 814-819
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC5554909
- OpenAlex
- W2740617468
- Cited by
- 35
- References
- 23
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 4 · 2019: 7 · 2018: 2
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM099594, TL4 GM118980)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, drug solubility, cellular uptake, Jurkat cells, A549 cells, anticancer drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines. https://app.cochat.ai/papers/10.1021/acsmedchemlett.7b00117
- The paper
- Ayalew, L., Acuna, J., Urfano, S. F., Morfin, C., Sablan, A., Oh, M., Gamboa, A., & Slowinska, K. (2017). Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.7b00117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.